Drs Budoff and Baum discuss the topline results of the ODYSSEY trial presented at the 2018 ACC meeting and hope for easier access to PCSK9 inhibitors for their high-risk patients.
Despite the abandonment of research by some pharmaceutical companies, Dr Isaacson is very hopeful about the future of Alzheimer disease treatment and prevention.
Dr Szczech discusses the emotional challenges that patients with CKD face in their transition to dialysis, and offers suggestions to PCPs and pharmacists who see these patients.